{"result": {"id": "4d204404-f86b-4170-86b2-7ca369d244c3", "choices": [{"finish_reason": "stop", "index": 0, "logprobs": null, "message": {"content": "(\"entity\"<|>CHINESE EXPERT CONSENSUS ON THE USE OF XUEZHIKANG<|>EVENT<|>A revised expert consensus document published in 2017\")  \n##  \n(\"entity\"<|>STRENGTH RANDOMIZED CLINICAL TRIAL<|>EVENT<|>A clinical trial comparing high-dose omega-3 fatty acids vs corn oil on cardiovascular events\")  \n##  \n(\"entity\"<|>EUROPEAN ATHEROSCLEROSIS SOCIETY TASK FORCE<|>ORGANIZATION<|>A task force providing guidance on lipid-modifying therapy\")  \n##  \n(\"entity\"<|>XUEZHIKANG<|>ORGANIZATION<|>A Chinese medicinal product discussed in the expert consensus\")  \n##  \n(\"entity\"<|>XUEZHITONG<|>ORGANIZATION<|>A medicinal product studied for its effects on hypertriglyceridemia\")  \n##  \n(\"entity\"<|>GYNOSTEMMA PENTAPHYLLUM<|>ORGANIZATION<|>A plant studied for its effects on dyslipidemia\")  \n##  \n(\"entity\"<|>HEDAN TABLET<|>ORGANIZATION<|>A Chinese medicinal product studied for its effects on lipid profiles\")  \n##  \n(\"entity\"<|>PEMAFIBRATE<|>ORGANIZATION<|>A drug studied for triglyceride lowering and cardiovascular risk reduction\")  \n##  \n(\"entity\"<|>NIACIN<|>ORGANIZATION<|>A drug studied for its effects on high-density lipoprotein composition and function\")  \n##  \n(\"entity\"<|>OMEGA-3 FATTY ACIDS<|>ORGANIZATION<|>A supplement studied for its effects on coronary artery disease\")  \n##  \n(\"entity\"<|>ICOSAPENT ETHYL<|>ORGANIZATION<|>A drug studied for cardiovascular risk reduction in hypertriglyceridemia\")  \n##  \n(\"entity\"<|>BEMPEDOIC ACID<|>ORGANIZATION<|>A drug studied for its effects on LDL cholesterol in high-risk patients\")  \n##  \n(\"relationship\"<|>CHINESE EXPERT CONSENSUS ON THE USE OF XUEZHIKANG<|>XUEZHIKANG<|>The consensus document provides guidelines on the use of Xuezhikang<|>8\")  \n##  \n(\"relationship\"<|>STRENGTH RANDOMIZED CLINICAL TRIAL<|>OMEGA-3 FATTY ACIDS<|>The trial studied the effects of omega-3 fatty acids on cardiovascular events<|>8\")  \n##  \n(\"relationship\"<|>EUROPEAN ATHEROSCLEROSIS SOCIETY TASK FORCE<|>PEMAFIBRATE<|>The task force provided guidance on lipid-modifying therapies including pemafibrate<|>7\")  \n##  \n(\"relationship\"<|>EUROPEAN ATHEROSCLEROSIS SOCIETY TASK FORCE<|>BEMPEDOIC ACID<|>The task force provided guidance on lipid-modifying therapies including bempedoic acid<|>7\")  \n##  \n(\"relationship\"<|>XUEZHITONG<|>GYNOSTEMMA PENTAPHYLLUM<|>Both are medicinal products studied for lipid management<|>5\")  \n##  \n(\"relationship\"<|>HEDAN TABLET<|>PEMAFIBRATE<|>Both are drugs studied for lipid profile improvement<|>5\")  \n##  \n(\"relationship\"<|>NIACIN<|>OMEGA-3 FATTY ACIDS<|>Both are studied for their effects on lipid metabolism<|>5\")  \n##  \n(\"relationship\"<|>ICOSAPENT ETHYL<|>BEMPEDOIC ACID<|>Both are drugs studied for cardiovascular risk reduction<|>5\")  \n<|COMPLETE|>", "refusal": null, "role": "assistant", "annotations": null, "audio": null, "function_call": null, "tool_calls": null}}], "created": 1751559304, "model": "deepseek-chat", "object": "chat.completion", "service_tier": null, "system_fingerprint": "fp_8802369eaa_prod0623_fp8_kvcache", "usage": {"completion_tokens": 870, "prompt_tokens": 5327, "total_tokens": 6197, "completion_tokens_details": null, "prompt_tokens_details": {"audio_tokens": null, "cached_tokens": 5248}, "prompt_cache_hit_tokens": 5248, "prompt_cache_miss_tokens": 79}}, "input": {"messages": [{"content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: 专家共识组 . 血脂康(胶囊)临床应 用中国专家共识(2017 修订版) [J]. 中华内科杂志, 2018, 57 (2):            97?100.             DOI:             10.3760/cma.           j. issn.0578?1426.2018.02.003.\n　Committee     of     Cardio?Cerebro?Vascular     Diseases     of Gerontological  Society  of  China,  the  Working   Group  of Chinese   Expert   Consensus   on  the   Use   of  Xuezhikang. Chinese expert consensus on the use of Xuezhikang (2017 revised edition)[J]. Chin J Intern Med, 2018, 57 (2):97?100. DOI: 10.3760/cma.j.issn.0578?1426.2018.02.003.\n[51]      Jia  W,  Li  Y,  Wan J,  et al.  Effects  of Xuezhitong  in  patients with   hypertriglyceridemia:   a   multicentre,   randomized, double?blind,    double    simulation,    positive     drug    and placebo  parallel  control  study[J].  Cardiovasc  Drugs  Ther, 2020,            34 (4):           525?534.            DOI:            10.1007/ s10557?020?06965?3.\n[52]      Dai  N,  Zhao  FF,  Fang  M, et al.  Gynostemma pentaphyllum for   dyslipidemia:   a   systematic   review   of   randomized controlled  trials[J].  Front  Pharmacol,  2022,   13: 917521. DOI: 10.3389/fphar.2022.917521.\n[53]      Xu RX, Wu NQ, Li S, et al. Effects of Hedan Tablet (荷丹片) on  lipid  profile,  proprotein  convertase  subtilisin/kexin type   9    and    high?density   lipoprotein    subfractions    in patients  with  hyperlipidemia:  a  primary  study[J].  Chin  J Integr    Med,     2016,    22 (9):    660?665.    DOI:     10.1007/ s11655?015?2140?3.\n[54]      Das  Pradhan  A,  Glynn  RJ,  Fruchart  JC,  et al.  Triglyceride lowering with  pemafibrate to  reduce  cardiovascular  risk [J].   N    Engl   J    Med,   2022,    387 (21):   1923?1934.    DOI: 10. 1056/NEJMoa2210645.\n[55]       Gordon   SM,  Amar   MJ,  Jeiran   K,   et al.   Effect   of  niacin monotherapy   on  high   density  lipoprotein   composition\n\n\nand function[J]. Lipids Health Dis, 2020,  19 (1): 190. DOI: 10.1186/s 12944?020?01350?3.\n[56]      Tadic  M,  Sala  C,  Grassi  G,  et al.  Omega?3  fatty  acids  and coronary artery disease: more questions than answers [J]. J     Clin     Med,     2021,     10 (11):    2495.     DOI:     10.3390/ jcm 10112495.\n[57]       Bhatt  DL,  Steg  PG,  Miller  M,  et al.   Cardiovascular  risk reduction  with  icosapent  ethyl  for  hypertriglyceridemia [J].  N  Engl  J   Med,  2019,  380 (1): 11?22.  DOI:  10.1056/ NEJMoa1812792.\n[58]      Nicholls SJ, Lincoff AM, Garcia M, et al. Effect of high?dose omega?3   fatty    acids    vs   corn   oil   on   major    adverse cardiovascular  events  in  patients  at  high  cardiovascular risk:  the  STRENGTH  Randomized  Clinical  Trial [J].  JAMA, 2020,         324 (22):         2268?2280.         DOI:          10.1001/ jama.2020.22258.\n[59]      Averna M, Banach M, Bruckert E, et al. Practical guidance for combination       lipid?modifying       therapy       in       high?and very?high?risk   patients:   a   statement   from   a   European Atherosclerosis Society Task Force [J]. Atherosclerosis,  2021, 325:99?109. DOI: 10.1016/j.atherosclerosis.2021.03.039.\n[60]      Goldberg AC, Leiter LA, Stroes E, et al. Effect of bempedoic acid vs  placebo  added to  maximally tolerated  statins  on low?density  lipoprotein  cholesterol  in  patients  at  high risk   for\n######################\nOutput:", "role": "user"}, {"role": "assistant", "content": "(\"entity\"<|>COMMITTEE OF CARDIO-CEREBRO-VASCULAR DISEASES OF GERONTOLOGICAL SOCIETY OF CHINA<|>ORGANIZATION<|>An organization involved in creating the Chinese expert consensus on the use of Xuezhikang\")  \n##  \n(\"entity\"<|>WORKING GROUP OF CHINESE EXPERT CONSENSUS ON THE USE OF XUEZHIKANG<|>ORGANIZATION<|>A working group responsible for the revised edition of the Chinese expert consensus on Xuezhikang\")  \n##  \n(\"entity\"<|>XUEZHIKANG<|>ORGANIZATION<|>A Chinese medicinal product discussed in the expert consensus\")  \n##  \n(\"entity\"<|>CHINESE EXPERT CONSENSUS ON THE USE OF XUEZHIKANG<|>EVENT<|>A revised expert consensus document published in 2017\")  \n##  \n(\"entity\"<|>JIA W<|>PERSON<|>A researcher involved in a study on Xuezhitong for hypertriglyceridemia\")  \n##  \n(\"entity\"<|>LI Y<|>PERSON<|>A researcher involved in a study on Xuezhitong for hypertriglyceridemia\")  \n##  \n(\"entity\"<|>WAN J<|>PERSON<|>A researcher involved in a study on Xuezhitong for hypertriglyceridemia\")  \n##  \n(\"entity\"<|>XUEZHITONG<|>ORGANIZATION<|>A medicinal product studied for its effects on hypertriglyceridemia\")  \n##  \n(\"entity\"<|>DAI N<|>PERSON<|>A researcher involved in a systematic review of Gynostemma pentaphyllum for dyslipidemia\")  \n##  \n(\"entity\"<|>ZHAO FF<|>PERSON<|>A researcher involved in a systematic review of Gynostemma pentaphyllum for dyslipidemia\")  \n##  \n(\"entity\"<|>FANG M<|>PERSON<|>A researcher involved in a systematic review of Gynostemma pentaphyllum for dyslipidemia\")  \n##  \n(\"entity\"<|>GYNOSTEMMA PENTAPHYLLUM<|>ORGANIZATION<|>A plant studied for its effects on dyslipidemia\")  \n##  \n(\"entity\"<|>XU RX<|>PERSON<|>A researcher involved in a study on Hedan Tablet for hyperlipidemia\")  \n##  \n(\"entity\"<|>WU NQ<|>PERSON<|>A researcher involved in a study on Hedan Tablet for hyperlipidemia\")  \n##  \n(\"entity\"<|>LI S<|>PERSON<|>A researcher involved in a study on Hedan Tablet for hyperlipidemia\")  \n##  \n(\"entity\"<|>HEDAN TABLET<|>ORGANIZATION<|>A Chinese medicinal product studied for its effects on lipid profiles\")  \n##  \n(\"entity\"<|>DAS PRADHAN A<|>PERSON<|>A researcher involved in a study on pemafibrate for cardiovascular risk reduction\")  \n##  \n(\"entity\"<|>GLYNN RJ<|>PERSON<|>A researcher involved in a study on pemafibrate for cardiovascular risk reduction\")  \n##  \n(\"entity\"<|>FRUCHART JC<|>PERSON<|>A researcher involved in a study on pemafibrate for cardiovascular risk reduction\")  \n##  \n(\"entity\"<|>PEMAFIBRATE<|>ORGANIZATION<|>A drug studied for triglyceride lowering and cardiovascular risk reduction\")  \n##  \n(\"entity\"<|>GORDON SM<|>PERSON<|>A researcher involved in a study on niacin monotherapy for HDL composition and function\")  \n##  \n(\"entity\"<|>AMAR MJ<|>PERSON<|>A researcher involved in a study on niacin monotherapy for HDL composition and function\")  \n##  \n(\"entity\"<|>JEIRAN K<|>PERSON<|>A researcher involved in a study on niacin monotherapy for HDL composition and function\")  \n##  \n(\"entity\"<|>NIACIN<|>ORGANIZATION<|>A drug studied for its effects on high-density lipoprotein composition and function\")  \n##  \n(\"entity\"<|>TADIC M<|>PERSON<|>A researcher involved in a study on omega-3 fatty acids and coronary artery disease\")  \n##  \n(\"entity\"<|>SALA C<|>PERSON<|>A researcher involved in a study on omega-3 fatty acids and coronary artery disease\")  \n##  \n(\"entity\"<|>GRASSI G<|>PERSON<|>A researcher involved in a study on omega-3 fatty acids and coronary artery disease\")  \n##  \n(\"entity\"<|>OMEGA-3 FATTY ACIDS<|>ORGANIZATION<|>A supplement studied for its effects on coronary artery disease\")  \n##  \n(\"entity\"<|>BHATT DL<|>PERSON<|>A researcher involved in a study on icosapent ethyl for hypertriglyceridemia\")  \n##  \n(\"entity\"<|>STEG PG<|>PERSON<|>A researcher involved in a study on icosapent ethyl for hypertriglyceridemia\")  \n##  \n(\"entity\"<|>MILLER M<|>PERSON<|>A researcher involved in a study on icosapent ethyl for hypertriglyceridemia\")  \n##  \n(\"entity\"<|>ICOSAPENT ETHYL<|>ORGANIZATION<|>A drug studied for cardiovascular risk reduction in hypertriglyceridemia\")  \n##  \n(\"entity\"<|>NICHOLLS SJ<|>PERSON<|>A researcher involved in the STRENGTH Randomized Clinical Trial on omega-3 fatty acids\")  \n##  \n(\"entity\"<|>LINCOFF AM<|>PERSON<|>A researcher involved in the STRENGTH Randomized Clinical Trial on omega-3 fatty acids\")  \n##  \n(\"entity\"<|>GARCIA M<|>PERSON<|>A researcher involved in the STRENGTH Randomized Clinical Trial on omega-3 fatty acids\")  \n##  \n(\"entity\"<|>STRENGTH RANDOMIZED CLINICAL TRIAL<|>EVENT<|>A clinical trial comparing high-dose omega-3 fatty acids vs corn oil on cardiovascular events\")  \n##  \n(\"entity\"<|>AVERNA M<|>PERSON<|>A researcher involved in a European Atherosclerosis Society Task Force statement\")  \n##  \n(\"entity\"<|>BANACH M<|>PERSON<|>A researcher involved in a European Atherosclerosis Society Task Force statement\")  \n##  \n(\"entity\"<|>BRUCKERT E<|>PERSON<|>A researcher involved in a European Atherosclerosis Society Task Force statement\")  \n##  \n(\"entity\"<|>EUROPEAN ATHEROSCLEROSIS SOCIETY TASK FORCE<|>ORGANIZATION<|>A task force providing guidance on lipid-modifying therapy\")  \n##  \n(\"entity\"<|>GOLDBERG AC<|>PERSON<|>A researcher involved in a study on bempedoic acid for LDL cholesterol reduction\")  \n##  \n(\"entity\"<|>LEITER LA<|>PERSON<|>A researcher involved in a study on bempedoic acid for LDL cholesterol reduction\")  \n##  \n(\"entity\"<|>STROES E<|>PERSON<|>A researcher involved in a study on bempedoic acid for LDL cholesterol reduction\")  \n##  \n(\"entity\"<|>BEMPEDOIC ACID<|>ORGANIZATION<|>A drug studied for its effects on LDL cholesterol in high-risk patients\")  \n##  \n(\"relationship\"<|>COMMITTEE OF CARDIO-CEREBRO-VASCULAR DISEASES OF GERONTOLOGICAL SOCIETY OF CHINA<|>WORKING GROUP OF CHINESE EXPERT CONSENSUS ON THE USE OF XUEZHIKANG<|>Both organizations are involved in creating the expert consensus on Xuezhikang<|>7\")  \n##  \n(\"relationship\"<|>WORKING GROUP OF CHINESE EXPERT CONSENSUS ON THE USE OF XUEZHIKANG<|>XUEZHIKANG<|>The working group created a consensus document on the use of Xuezhikang<|>8\")  \n##  \n(\"relationship\"<|>JIA W<|>XUEZHITONG<|>Jia W researched the effects of Xuezhitong<|>6\")  \n##  \n(\"relationship\"<|>DAI N<|>GYNOSTEMMA PENTAPHYLLUM<|>Dai N conducted a systematic review on Gynostemma pentaphyllum<|>6\")  \n##  \n(\"relationship\"<|>XU RX<|>HEDAN TABLET<|>Xu RX studied the effects of Hedan Tablet on lipid profiles<|>6\")  \n##  \n(\"relationship\"<|>DAS PRADHAN A<|>PEMAFIBRATE<|>Das Pradhan A researched the effects of pemafibrate on cardiovascular risk<|>6\")  \n##  \n(\"relationship\"<|>GORDON SM<|>NIACIN<|>Gordon SM studied the effects of niacin on HDL composition<|>6\")  \n##  \n(\"relationship\"<|>TADIC M<|>OMEGA-3 FATTY ACIDS<|>Tadic M researched the effects of omega-3 fatty acids on coronary artery disease<|>6\")  \n##  \n(\"relationship\"<|>BHATT DL<|>ICOSAPENT ETHYL<|>Bhatt DL studied the effects of icosapent ethyl on hypertriglyceridemia<|>6\")  \n##  \n(\"relationship\"<|>NICHOLLS SJ<|>STRENGTH RANDOMIZED CLINICAL TRIAL<|>Nicholls SJ was involved in the STRENGTH trial<|>8\")  \n##  \n(\"relationship\"<|>AVERNA M<|>EUROPEAN ATHEROSCLEROSIS SOCIETY TASK FORCE<|>Averna M was part of the European Atherosclerosis Society Task Force<|>8\")  \n##  \n(\"relationship\"<|>GOLDBERG AC<|>BEMPEDOIC ACID<|>Goldberg AC studied the effects of bempedoic acid on LDL cholesterol<|>6\")  \n<|COMPLETE|>"}, {"content": "MANY entities and relationships were missed in the last extraction. Remember to ONLY emit entities that match any of the previously extracted types. Add them below using the same format:\n", "role": "user"}], "parameters": {"model": "deepseek-chat", "frequency_penalty": 0.0, "max_tokens": 4000, "n": 1, "presence_penalty": 0.0, "temperature": 0.0, "top_p": 1.0}}, "key": "chat_extract-continuation-0_afc6be0c1aadeaa9fb55278c4fd491677b1503681606e0f1e3ced0d3dffd3a40_v2"}